Please ensure Javascript is enabled for purposes of website accessibility

Why Computer Sciences, Sarepta Therapeutics, and Nimble Storage Jumped Today

By Dan Caplinger - May 25, 2016 at 5:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks led the market higher. Find out why.

Image source: Nimble Storage.

The stock market kept moving higher on Wednesday, adding to gains from the previous trading session as investors became increasingly comfortable with the idea that the global economy might not slow down as much as some had feared. Energy prices continued to regain ground from their 2015 crash, and crude oil prices in the U.S. are approaching the $50 per barrel mark for the first time all year. Amid all the enthusiasm in the market, some individual stocks produced truly outstanding results for their shareholders. Among the best performers Wednesday were Computer Sciences (CSC), Sarepta Therapeutics (SRPT 0.40%), and Nimble Storage (NYSE: NMBL).

Computer Sciences soared 42% after Tuesday afternoon's announcement that it would work with Hewlett-Packard Enterprise on what it referred to as a "spin-merger." The transaction will involve HP Enterprise spinning off its enterprise services business, and then having it merge with Computer Sciences to form a pure-play global IT services company. The net result of the deal will be that HP Enterprise shareholders will own about a 50% stake in the post-merger Computer Sciences. As Computer Sciences CEO Mike Lawrie described it, the two companies together "will have the scale, foundation, and next-generation technologies to innovate, compete, and grow in a rapidly changing marketplace." The companies expect the deal to close by the end of the first quarter of 2017, and it should result in no adverse tax consequences to shareholders of either company.

Sarepta Therapeutics jumped 27% in the wake of a decision from the Food and Drug Administration to delay its consideration of the company's Duchenne muscular dystrophy drug eteplirsen. The drug had received an unfavorable recommendation from an FDA advisory panel, with a 7-6 vote finally deciding that it failed to demonstrate a clinical benefit in dystrophin production. A 7-3 vote, with three abstentions, found that eteplirsen was not effective in treating the condition. Given the likelihood that the FDA would simply follow the advisory panel's decision and reject the drug, many speculated that the delay might be due to FDA efforts to find reasons to support the drug. If the FDA chooses to approve eteplirsen, then the previous advisory panel recommendation will be irrelevant, and investors clearly hope that that will be the eventual outcome.

Finally, Nimble Storage finished the day up 16%. The data-storage company's fiscal first-quarter report included a better than 20% gain in revenue, and even though that resulted in a net loss of more than $20 million, the bottom-line figure was actually better than many had feared. Even though Nimble Storage is losing money, many believe that its strategy of sacrificing short-term earnings in order to build up a loyal customer base and claim market share from its rivals is the best response in a competitive market. Eventually, Nimble Storage will have to find ways to make profits, but for now, investors are celebrating the company's vision and believe that it's on the right path strategically to maximize its long-term opportunities.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$69.50 (0.40%) $0.28
DXC Technology Stock Quote
DXC Technology

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.